Ad image

Wall Street’s top analyst calls

9 Min Read

The most talked about research calls around Wall Street and travel to the market is currently in one place. As edited by Frye, here is today’s research call that investors need to know:

Top 5 Upgrades:

  • Argus has been upgraded Nike (NKE) Buy from hold at a price target of $85. Nike’s stock recovery is currently underway as the company uses e-commerce channels to improve pricing, the company tells investors in a research note.

  • Raymond James has upgraded Hyatt (h) A strong buy from the market will perform at a price target of $165, following the announcement that it has reached a contract to sell the entire Playa-owned property.

  • Goldman Sachs has been upgraded Hasbro (has) Buy from neutral with a price target of $66 to $85. The company is well positioned to exceed consensus expectations beyond revenues since 2026, adjusted EBITDA and free cash flow driven by magical robust demand. New Universes beyond the new universe set of the rally, implementation of the company’s new issued digital game strategy, and toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to perform toy relief, to execute on the company’s new digital game strategy, and to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to execute on the company’s new digital game strategy, and to execute on the company’s new digital game strategy, and to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request toy relief, to request to

  • Barclays upgraded Ionis Pharmaceuticals (Aeon) In September, it will likely be on the rise of Tryngolza Phase 3 Core/Core2 data in severe hypertriglyceridemia scheduled for September, from equal weight to overweight with a price target of $57 to $57.

  • Wells Fargo has been upgraded Sinta (CTAS) equals weight from underweight with a price target of $196 to $221. The company says it weathered macros that are tougher than its peers, and Wells sees an attractive opportunity for Sinta to drive profits from its share.

Top 5 Downgrades:

  • Goldman Sachs has been downgraded Textron (TXT) Neutral from purchases with a price target of $95 to $85. The company still believes that supply and demand for business jets is tight and that FLRAA’s victory is a major new revenue contributor, but the benefits of the stock have not yet been realized.

  • TD Cowen is downgraded Sweet Green (SG) Hold from purchases with price targets of $25 to $15. The company says concerns about mis-sales at the same store began in the second quarter, but expanded to an optimistic acceleration in 2025, while risking it would not return to the same store sales in 2026.

  • KeyBanc has been downgraded system (Line) From overweight to sector weight without price targets. Given the challenging operating environment caused by softer demand and rising levels of new supply, cold storage REITs are unfavourable and the outlook for stabilizing conditions remains uncertain, the company told investors in its research notes.

  • Goldman Sachs has been downgraded Kotera Energy (CTRA) Price target of $31 is unchanged from purchases neutral. Over the past few months, Coterra has been trading more closely with oil producer peers, and as a result, the company added that gas-centric E&P peers are inadequate given the gas-centric E&P peers, which are relatively positive for gas-to-oil outlook.

  • UBS has been downgraded South Copper (SCCO) from purchase to neutral with a price target of $105. UBS feels negative risk to copper prices over the next six months due to macro uncertainty and trade war issues. The risk of rising is limited, and stocks currently believe that they are “balanced in risk rewards.”

Starting Top 5:

  • Truist has begun reporting on Sportradar (SRAD) Purchase rating and price target of $33. Sportradar, as the biggest B2B partner in the sports betting industry, is “increasingly important” to customers, including operators, leagues and media, the company says.

  • Truist has begun reporting on Genius Sports (geni) Purchase rating and price target of $14. The company considers the genius to be an “integrated B2B partner” in the online sports betting industry. This sees a “trusted path” to approach around $300 million in EBITDA by 2028.

  • Roth Capital has begun compensation for Mastic (MTZ) Purchase rating and price target of $210. Engineering, procurement and construction companies provide infrastructure solutions for the electricity/gas utilities, renewable energy, communications and pipeline industries. This is what Mastec considers “one of the best companies to help accelerate the construction of electrical infrastructure.”

  • Goldman Sachs has begun reporting Omada Health (OMDA) Purchase rating and price target of $29. Given the growth trajectory, the short-term path to profitability, and the peer ratings below, companies are looking at stocks offering “persuasive risk/reward” at current levels. Morgan Stanley, Barclays, JPMorgan, Needham and Canaccord also began compensation for their shares with comparable valuations.

  • Piper Sandler has begun reporting on Rollins (ROL) Overweight rating and $70 price target. With a long track record of “healthy and sustainable growth,” Rollins is in the early stages of a transition from a family-owned business to a more modernized public company, accelerating growth and “makes stocks more attractive,” the company said.

First published fly – The ultimate source of financial news that moves to the market in real time. Try it now >>

See insider hot stocks on Tipranks >>

Read more about NKE:

Disclaimer and disclosureReport the problem

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Exit mobile version